|
US2017355763A1
|
|
Use of IL-31 monoclonal antibodies for reducing pruritus
|
|
US2016060323A1
|
|
ZCYTOR17 heterodimeric cytokine receptor
|
|
US2015037331A1
|
|
Il-31 monoclonal antibodies
|
|
AU2013204175A1
|
|
Methods of Treating Pain and Inflammation in Neuronal Tissue Using IL-31 Antagonists
|
|
JP2013067619A
|
|
Antibody that binds to both il-17a and il-17f and method of using the same
|
|
AU2012202219A1
|
|
Novel Cytokine Zcytor17 Ligand
|
|
AU2012202218A1
|
|
Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
|
|
AU2011265468A1
|
|
Compositions and methods for modulating immune responses
|
|
EP2580238A1
|
|
Dimeric vstm3 fusion proteins and related compositions and methods
|
|
US2011039268A1
|
|
Cytokine protein family
|
|
CN102448984A
|
|
Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
|
|
EP2350124A1
|
|
Il-29 mutants and uses thereof
|
|
EP2344546A1
|
|
Single chain fc type iii interferons and methods of using same
|
|
EP2623112A1
|
|
Soluble hybrid Fc gamma receptors and related methods
|
|
SI2291657T1
|
|
Levels of blys/april heterotrimers in serum and use in diagnostic methods
|
|
CA2716738A1
|
|
Thrombin activator compositions and methods of making and using the same
|
|
AU2009228158A1
|
|
Compositions and methods for inhibiting PDGFRbeta and VEGF-A
|
|
WO2009123903A1
|
|
Hemostatic microspheres
|
|
US2009155271A1
|
|
IL-17A and IL-17F antagonists
|
|
WO2009102840A1
|
|
Prostate secretory protein and its domains as frameworks for novel binding molecules
|
